Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2013

Filing Date
Filed February 11, 2014
Period End
December 31, 2013
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 11, 2014. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported a net loss of $46.1 milliona, or $0.69 per share, for 2013, compared with net income of $5.0 million in 2012 and $37.6 million in 2011.

Total revenues fell to $2.9 millionb in 2013 from $53.1 million in 2012 and $77.4 million in 2011, as collaboration revenue from AbbVie and Boehringer Ingelheim tapered off after their collaborative development and research periods ended in 2012. The company stated it does not expect to recognize any milestone revenue in 2014 and expects revenue to decline further, with a net loss again in 2014. Research and development expense rose to $39.2 million in 2013 from $37.2 million in 2012, driven mainly by external development spending on the VMAT2 program.

The company's lead programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II for uterine fibroids, partnered with AbbVie, and a wholly owned VMAT2 inhibitor (NBI-98854) in Phase II for tardive dyskinesia. Under the AbbVie agreement, the company received an $75 million upfront payment and is eligible for up to $480 millionc in development and regulatory payments and up to $50 million in commercial payments. At December 31, 2013, cash, cash equivalents and investments totaled $145.7 million, and the company had no outstanding debt.

The company stated that existing capital resources, investment income and future alliance payments are expected to be sufficient for at least the next 12 months. The accumulated deficit was $765.8 milliond at year-end.

The filing also describes the Kinect and Kinect 2 Phase IIb trials of NBI-98854, where the 2014 end-of-Phase II meeting request is expected to be filed in the first half of 2014. The company had approximately 81 full-time employees at December 31, 2013 and reported no material legal proceedings.

Key Highlights

  1. Net loss of $46.1 million ($0.69 per share) in 2013, versus net income of $5.0 million in 2012 and $37.6 million in 2011
  2. Total revenues fell to $2.9 million in 2013 from $53.1 million in 2012; the company does not expect milestone revenue in 2014
  3. R&D expense rose to $39.2 million in 2013 from $37.2 million in 2012, mainly from VMAT2 external development costs
  4. Elagolix (GnRH antagonist, partnered with AbbVie) is in Phase III for endometriosis, with an NDA filing expected in 2016 per the filing
  5. AbbVie collaboration: $75 million upfront, with up to $480 million in development and regulatory payments and up to $50 million in commercial payments
  6. Cash, cash equivalents and investments of $145.7 million at December 31, 2013, with no outstanding debt and an accumulated deficit of $765.8 million
  7. Company expects existing capital resources and alliance payments to fund operations for at least the next 12 months, and a $150 million shelf registration is in place

Financial Statements

FY2013 against FY2012

Line itemFY2013FY2012Change
Revenue$2.92M$53.14M−94.5%
R&D Expenses$39.25M$37.16M+5.6%
Operating Expenses$52.60M$51.69M+1.8%
Operating Income-$49.68M$1.45M−3530.8%
Net Income-$46.09M$5.03M−1017.2%
EPS (Basic)$-0.69$0.08−962.5%
EPS (Diluted)$-0.69$0.08−962.5%
Shares Outstanding (Basic)66.99M65.62M+2.1%
Shares Outstanding (Diluted)66.99M66.95M+0.1%

Frequently Asked Questions

  1. Why did revenue decline so sharply in 2013?

    Revenue fell to $2.9 million from $53.1 million because the collaborative development portion of the AbbVie agreement ended on December 31, 2012, and the collaborative research portion with Boehringer Ingelheim ended in June 2012. The filing states that 2013 revenue consisted only of amortization of the DSP up-front license fee.

  2. What are the company's most advanced clinical programs?

    The lead programs are elagolix, a GnRH antagonist in Phase III for endometriosis and Phase II for uterine fibroids, partnered with AbbVie, and NBI-98854, a wholly owned VMAT2 inhibitor in Phase II for tardive dyskinesia. The filing says the company intends to maintain certain commercial rights to the VMAT2 inhibitor.

  3. Does the company expect to be profitable soon?

    No. The filing states the company does not expect to be profitable or generate positive operating cash flow for 2014 or the foreseeable future, and expects a net loss in 2014 due to lower collaboration revenue and higher R&D and share-based compensation expense.

  4. Does the company have enough cash to fund operations?

    The company believes its existing capital resources, investment income and future payments under strategic alliances will be sufficient for at least the next 12 months. It also notes that it may need additional funding and has a shelf registration allowing up to $150 million in securities offerings.

  5. What are the key risks highlighted in the filing?

    Key risks include clinical trial failure or delay, dependence on collaborators such as AbbVie, limited sales and marketing experience, reliance on third-party contract manufacturers, intense competition, patent protection uncertainty, and potential product liability exposure beyond limited insurance coverage of $10 million per occurrence and in the aggregate.